Advertisement
ANVS vs DMAC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANVS is a Buy and DMAC is a StrongBuy.
ANVS's Stochastic Oscillator sits in oversold zone for 10 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANVS advanced for three days, in 192 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANVS as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ANVS turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 43 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ANVS entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.630) is normal, around the industry mean (2.978). P/E Ratio (-0.549) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ANVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DMAC's Stochastic Oscillator sits in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
DMAC moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DMAC crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 19 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 218 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 123 of 157 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for DMAC moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DMAC as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for DMAC turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.195) is normal, around the industry mean (2.978). P/E Ratio (-12.042) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ANVS | DMAC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 47 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 12 | 55 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANVS's Valuation (12) in the null industry is somewhat better than the same rating for DMAC (70) in the Biotechnology industry. This means that ANVS’s stock grew somewhat faster than DMAC’s over the last 12 months.
DMAC's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for ANVS (100) in the null industry. This means that DMAC’s stock grew somewhat faster than ANVS’s over the last 12 months.
DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as ANVS (100) in the null industry. This means that DMAC’s stock grew similarly to ANVS’s over the last 12 months.
DMAC's Price Growth Rating (50) in the Biotechnology industry is in the same range as ANVS (50) in the null industry. This means that DMAC’s stock grew similarly to ANVS’s over the last 12 months.
ANVS's P/E Growth Rating (12) in the null industry is somewhat better than the same rating for DMAC (55) in the Biotechnology industry. This means that ANVS’s stock grew somewhat faster than DMAC’s over the last 12 months.
| ANVS | DMAC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 81% |
| Advances ODDS (%) | 16 days ago 79% | 12 days ago 84% |
| Declines ODDS (%) | 2 days ago 90% | 7 days ago 81% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANVS’s FA Score shows that 2 FA rating(s) are green while DMAC’s FA Score has 0 green FA rating(s).
- ANVS’s FA Score: 2 green, 3 red.
- DMAC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANVS’s TA Score shows that 3 TA indicator(s) are bullish while DMAC’s TA Score has 7 bullish TA indicator(s).
- ANVS’s TA Score: 3 bullish, 4 bearish.
- DMAC’s TA Score: 7 bullish, 4 bearish.
Price Growth
ANVS (@Biotechnology) experienced а -7.71% price change this week, while DMAC (@Biotechnology) price change was +10.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
Reported Earning Dates
ANVS is expected to report earnings on Nov 11, 2026.
DMAC is expected to report earnings on Nov 18, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ANVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANVS has been loosely correlated with ADXN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANVS jumps, then ADXN could also see price increases.
| Ticker / NAME | Correlation To ANVS | 1D Price Change % | ||
|---|---|---|---|---|
| ANVS | 100% | +1.91% | ||
| ADXN - ANVS | 43% Loosely correlated | +3.04% | ||
| JAZZ - ANVS | 38% Loosely correlated | +2.56% | ||
| DMAC - ANVS | 37% Loosely correlated | +10.17% | ||
| MDGL - ANVS | 36% Loosely correlated | +4.57% | ||
| AMLX - ANVS | 34% Loosely correlated | +5.27% | ||
More | ||||
DMAC and
Correlation & Price change
A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with TSHA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then TSHA could also see price increases.
| Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
|---|---|---|---|---|
| DMAC | 100% | +10.17% | ||
| TSHA - DMAC | 44% Loosely correlated | +4.31% | ||
| EDIT - DMAC | 44% Loosely correlated | +6.61% | ||
| VIR - DMAC | 44% Loosely correlated | +5.19% | ||
| ANNX - DMAC | 43% Loosely correlated | -4.49% | ||
| SLDB - DMAC | 41% Loosely correlated | +8.11% | ||
More | ||||